While it may be advantageous to capture GBM-specific EVs from the circulation using known markers, such as EGFR/EGFRvIII, beyond the direct impacts on cortical tissues, GBM inflicts a substantial systemic toll [69] that is perhaps better capitulated in total circulating EV populations. This evidence concerns the gene EGFR and glioblastoma.